Blue Water Ventures International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BWVI research report →
Price Chart
About the company
Blue Water Ventures International, Inc. specializes in the archaeologically sensitive recovery of cargo, artifacts, and treasures from various shipwrecks. Each project is undertaken with extensive research and due diligence, primarily focusing on search and recovery efforts in shallow waters.
- CEO
- Neilank K. Jha
- IPO
- 2007
- Employees
- 5
- HQ
- Fort Lauderdale, FL, US
Get TickerSpark's AI analysis on BWVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $181.67K
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -1.00
- EV/EBITDA
- 0.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 47065.55%
- ROIC
- 13590.96%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,826+0.0%
- Op Income
- $-11,354,979
- Net Income
- $-16,979,840-1100.3%
- EPS
- $-0.08-292.7%
- OCF Growth
- -298.0%
- FCF Growth
- -298.0%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.40
- RSI (14)
- 95
- Avg Volume
- 12.17K
No earnings-call transcripts are available for BWVI yet.
- Free Float
- 7.0%
- Shares Outstanding
- 302.79M
- Float Shares
- 21.10M
Our BWVI coverage
Recent articles, reports, and earnings notes.
No research on BWVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BWVI report →Historical Regulatory Filing Deficiences Continue to Stifle Psycheceutical Biosciences
accesswire.com · May 16
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
accesswire.com · Jan 17
Dr. Neilank Jha Appointed as Executive Chairman and Chief Executive Officer of Psycheceutical Bioscience Inc.
accesswire.com · Dec 12
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
accesswire.com · Aug 10
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
accesswire.com · Aug 1
First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
accesswire.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.